Incyte Co. (INCY) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its position in Incyte Co. (NASDAQ:INCY) by 40.2% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,001 shares of the biopharmaceutical company’s stock after selling 4,703 shares during the period. SG Americas Securities LLC’s holdings in Incyte were worth $602,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. National Pension Service increased its position in Incyte by 4.7% in the 4th quarter. National Pension Service now owns 222,084 shares of the biopharmaceutical company’s stock valued at $18,526,000 after buying an additional 9,960 shares in the last quarter. Bank of Montreal Can increased its position in Incyte by 20.4% in the 4th quarter. Bank of Montreal Can now owns 239,587 shares of the biopharmaceutical company’s stock valued at $15,236,000 after buying an additional 40,525 shares in the last quarter. Bronfman E.L. Rothschild L.P. increased its position in Incyte by 46.3% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 730 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 231 shares in the last quarter. Norinchukin Bank The increased its position in Incyte by 45.2% in the 4th quarter. Norinchukin Bank The now owns 32,950 shares of the biopharmaceutical company’s stock valued at $2,095,000 after buying an additional 10,256 shares in the last quarter. Finally, Nissay Asset Management Corp Japan ADV increased its position in Incyte by 4.6% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 13,603 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 595 shares in the last quarter. 92.20% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Paula J. Swain sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $86.68, for a total value of $866,800.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 17.10% of the stock is owned by insiders.



INCY has been the subject of a number of analyst reports. Argus lifted their price target on Incyte from $83.00 to $98.00 and gave the company a “buy” rating in a research note on Monday, February 25th. Royal Bank of Canada downgraded Incyte from an “outperform” rating to a “sector perform” rating and set a $89.00 price target for the company. in a research note on Wednesday, April 3rd. They noted that the move was a valuation call. BidaskClub downgraded Incyte from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Oppenheimer set a $85.00 price target on Incyte and gave the company a “hold” rating in a research note on Sunday, April 7th. Finally, Raymond James set a $100.00 price target on Incyte and gave the company a “buy” rating in a research note on Friday, February 15th. Thirteen analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $91.07.

Shares of NASDAQ INCY opened at $78.68 on Wednesday. Incyte Co. has a twelve month low of $57.00 and a twelve month high of $88.83. The company has a market capitalization of $16.87 billion, a PE ratio of 95.95 and a beta of 1.31. The company has a current ratio of 5.22, a quick ratio of 5.21 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.33 by $0.29. Incyte had a return on equity of 13.28% and a net margin of 12.66%. The firm had revenue of $497.86 million for the quarter, compared to the consensus estimate of $488.00 million. During the same quarter in the previous year, the business earned ($0.01) EPS. The company’s revenue was up 30.2% compared to the same quarter last year. On average, analysts forecast that Incyte Co. will post 1.78 EPS for the current fiscal year.

WARNING: “Incyte Co. (INCY) Shares Sold by SG Americas Securities LLC” was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://dakotafinancialnews.com/2019/05/22/incyte-co-incy-shares-sold-by-sg-americas-securities-llc.html.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Story: What is dividend yield?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.